An observational study in Ischemic Stroke, sponsored by Dongzhimen Hospital, Beijing. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-11.
Sponsored by Dongzhimen Hospital, Beijing · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing — 6 open to participants now, 6 under way, none of them phase 3. Ischemic Stroke · Dongzhimen Hospital, Beijing.
Among the 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing, this one is one of 2 that started in 2023, is one of 6 observational ones, and was the 12th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →6 of the 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing are open now, in 2 countries. Recruiting first, the newest first:
Dongzhimen Hospital, Beijing · Sites in China
Ages 18–80
Dongzhimen Hospital, Beijing · Sites in China
Ages 50–80 · Healthy volunteers
Dongzhimen Hospital, Beijing · Sites in Canada
Ages 18–70
Dongzhimen Hospital, Beijing · Sites in China
Ages 18–80
Dongzhimen Hospital, Beijing · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 4 3
First in 2013; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 1,000 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 456 across the 10 interventional studies, 1,000 across the 6 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Dongzhimen Hospital, Beijing is the lead sponsor of 45 studies on the registry; 19 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.
Suhexiang Pill, a traditional Chinese patent medicine, is widely used in China for acute stroke. However, there is a lack of evidence of its efficacy and safety for acute ischemic stroke in real-world setting. This registry study will recruit 1000 patients who receive Suhexiang Pill treatment after acute ischemic stroke.
Patients diagnosed with Acute ischemic stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Suhexiang Pill is an approved traditional Chinese patent medicine.
Proportion of patients independent
Proportion of patients independent is defined as the modified Rankin Scale score of 0, 1, or 2.
Time frame: 90 days
National Institute of Health Stroke Scale
The National Institute of Health Stroke Scale (NIHSS) ranges from 0 to 42, with higher scores indicating more severe neurological deficits.
Time frame: The change from baseline to day 10 or discharge.
Glasgow Coma Scale
The Glasgow Coma Scale (GCS) is used to describe the extent of impaired consciousness in all types of acute medical and trauma patients, ranging from 0 to 15, with lower scores indicating more severe impaired consciousness.
Time frame: The change from baseline to day 10 or discharge.
Patient reported outcome
The patient reported outcome (PRO) scale of stroke consists of four dimensions including the influence on physical, emotional, and social functioning, as well as the overall satisfaction with treatment.
Time frame: At day 10 or discharge.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Dec 2024, 18 months after the start.
Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 18 months is below that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dongzhimen Hospital, Beijing